Interpreting estrogen screening assays in the context of potency and human exposure relative to natural exposures to phytoestrogens

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 101, Issue 1, 2014, Pages 114-124

  Becker, Richard A ^a   Hays, Sean M ^b   Kirman, Christopher R ^b   Aylward, Lesa L ^b   Wise, Kimberly ^a  

^a AMERICAN CHEMISTRY COUNCIL   (United States)

^b LLP   (United States)

Author keywords

Biomonitoring; Endocrine disruption; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; PHYTOESTROGEN;

ANALYSIS; BIOASSAY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMAN; PROCEDURES; URINE;

BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMANS; PHYTOESTROGENS;

EID: 84894232007     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.21085     Document Type: Article

References (57)

1. Aylward LL, Hays SM. 2008. Biomonitoring equivalents (BE) dossier for 2, 4-dichlorophenoxyacetic acid (2, 4-D) (CAS No. 94-75-7). Regul Toxicol Pharmacol 51(3 Suppl):S37-S48.
2. Aylward LL, Hays SM. 2011. Consideration of dosimetry in evaluation of ToxCast™ data. J Appl Toxicol. 31(8):741-751.
3. Aylward LL, Becker RA, Kirman CR, Hays SM. 2011. Assessment of margin of exposure based on biomarkers in blood: an exploratory analysis. Regul Toxicol Pharmacol 61:44-52.
4. Aylward LL, Kirman CR, Schoeny R, Portier CJ, Hays SM. 2013. Evaluation of biomonitoring data from the CDC National Exposure Report in a risk assessment context: perspectives across chemicals. Environ Health Perspect 121:287-294.
5. Aylward LL, Kirman CR, Adgate JL, McKenzie LM, Hays SM. 2012. Interpreting variability in population biomonitoring data: role of elimination kinetics. J Expo Sci Environ Epidemiol 22(4):398-408.
6. Basli A, Soulet S, Chaher N, Mérillon JM, Chibane M, Monti JP, Richard T. 2012. Wine polyphenols: potential agents in neuroprotection. Oxid Med Cell Longev 2012:805762, pages 1-14.
7. Bolt HM, Janning P, Michna H, Degen GH. 2001. Comparative assessment of endocrine modulators with oestrogenic activity: I. Definition of a hygiene-based margin of safety (HBMOS) for xeno-oestrogens against the background of European developments. Arch Toxicol 74(11):649-662.
8. Borgert CJ, LaKind JS, Witorsch RJ. 2003. A critical review of methods for comparing estrogenic activity of endogenous and exogenous chemicals in human milk and infant formula. Environ Health Perspect 111(8):1020-1036.
9. Borgert CJ, Mihaich EM, Quill TF, Marty MS, Levine SL, Becker RA. 2011a. Evaluation of EPA's Tier 1 endocrine screening battery and recommendations for improving the interpretation of screening results. Regul Toxicol Pharmacol. 59:397-411.
10. Borgert CJ, Mihaich EM, Ortego LS, Bentley KS, Holmes CM, Levine SL, Becker RA. 2011b. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program. Regul Toxicol Pharmacol 61:185-191.
11. Borgert CJ, Sargent EV, Casella G, Dietrich DR, McCarty LS, Golden RJ. 2012. The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol 62:313-328.
12. Borgert CJ, Baker SP, Matthews JC. 2013. Potency matters: thresholds govern endocrine activity. Regul Toxicol Pharmacol 67:83-88.
13. Caldwell DJ, Mastrocco F, Nowak, E, Johnston J, Yekel H, Pfeiffer D, Hoyt M, DuPlessie BM, Anderson PD. 2010. An assessment of potential exposure and risk from estrogens in drinking water. Environ Health Perspect. 118:338-344.
14. Carbonel AA, Simões RS, Santos RH, Baracat MC, Simões Mde J, Baracat EC, Soares Júnior JM. 2011. Effects of high-dose isoflavones on rat uterus. Rev Assoc Med Bras 57(5):534-539.
15. CDC. 2009. Laboratory procedure manual, analyte: benzophenone-3, bisphenol A, 2, 4-dichlorophenol, 2, 5-dichlorophenol, ortho-phenylphenol, methyl-, ethyl-, propyl-, and butyl parabens, 4-tertoctylphenol, 2, 4, 5-trichlorophenol, 2, 4, 6- trichlorophenol, triclosan, Matrix: Urine, Method No: 6301.01. Available at: http://www. cdc.gov/nchs/data/nhanes/nhanes_05_06/eph_d_met_phenols_ parabens.pdf. Accessed Nov. 25. 2013.
16. CDC. 2013. Fourth National Report on Human Exposure to Environmental Chemicals, updated tables, March, 2013. Available at: http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Mar2013.pdf. Accessed Nov. 25. 2013.
17. Charles GD, Gennings C, Tornesi B, Kan HL, Zacharewski TR, Bhaskar Gollapudi B, Carney EW. 2007. Analysis of the interaction of phytoestrogens and synthetic chemicals: an in vitro/in vivo comparison. Toxicol Appl Pharmacol 218(3):280-288.
18. Diel P, Schulz T, Smolnikar K, Strunck E, Vollmer G, Michna H. 2000. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J Steroid Biochem Mol Biol 73(1-2):1-10.
19. EFSA. 2008. EFSA panel on contaminants in the food chain: glucosinolates as undesirable substances in animal feed. Scientific Panel on Contaminants in the Food Chain. EFSA J 590:1-76.
20. EPA. 1998. EDSTAC final report, chapter three, conceptual framework and principles. Page 3-16. Available at: http://www.epa.gov/endo/pubs/edstac/chap3v14.pdf. Accessed Nov. 25, 2013.
21. EPA. 2009. Endocrine Disruptor Screening Program Test Guidelines, OPPTS 890.1600: uterotrophic assay. Available at: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series890.htm. Accessed Nov. 25, 2013.
22. EPA. 2011. Endocrine disruptor screening program, weight-of-evidence: evaluating results of EDSP Tier 1 screening to identify the need for Tier 2 testing. Available at: http://www.epa.gov/endo/. Accessed Nov. 25, 2013.
23. EPA. 2012a. Benchmark dose technical guidance. Available at: http://www.epa.gov/raf/publications/pdfs/benchmark_ dose_guidance.pdf. Accessed Nov. 25, 2013.
24. EPA. 2012b. EPA 2012. TSCA workplan chemical risk assessment, N-methylpyrrolidone: paint stripping use. December 2012. Available at: http://www.epa.gov/oppt/existingchemicals/pubs/TSCA_ Workplan_Chemical_Risk_Assessment_of_NMP.pdf. Accessed Nov. 25, 2013.
25. EPA. 2013a. Endocrine Disruptor Screening Program (EDSP). Available at: http://www.epa.gov/endo/index.htm. Accessed Nov. 25, 2013.
26. EPA. 2013b. Series 890-endocrine disruptor screening program test guidelines. Available at: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series890.htm. Accessed Nov. 25, 2013.
27. EPA. 2013b. Overview of the second list of chemicals for Tier 1 screening. http://www.epa.gov/endo/pubs/prioritysetting/list2facts.htm. Accessed Nov. 25, 2013.
28. EPF. 2013a. Endocrine Policy Forum comments on "Endocrine Disruptor Screening Program (EDSP) Evaluation of Tier 1 Screening Assays and Battery Performance, May 20, 2013." Available at: http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2013-0075-0013. Accessed November 25, 2013.
29. EPF. 2013b. Endocrine policy forum comments on weight-of-evidence: evaluating results of the EDSP Tier 1 screening. Available at: http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2013-0230-0011. Accessed Nov. 25, 2013.
30. Hays SM, Becker RA, Leung HW, Aylward LL, Pyatt DW. 2007. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul Toxicol Pharmacol 47(1):96-109.
31. Hays SM, Aylward LL, LaKind JS, Bartels MJ, Barton HA, Boogaard PJ, et al. 2008. Guidelines for the derivation of biomonitoring equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol 51(3 Suppl):S4-S15.
32. Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, Van Der Kraak G, Wade MG, Willett CE, Andersen ME, Borgert CJ, Coady KK, Dourson ML, Fowle III JR, Gray LE, Lamb JC, Ortego LS, Schug TS, Toole CM, Zorrilla LM, Kroner OL, Patterson J, Rinckel LA and Jones BR. 2013. Lessons Learned, Challenges, and Opportunities: The U.S. Endocrine Disruptor Screening Program. ALTEX. In Press.
33. Kanno J, Onyon L, Haseman J, Fenner-Crisp P, Ashby J, Owens W. 2001. The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: phase 1. Environ Health Perspect 109(8):785-794.
34. Kanno J, Onyon L, Peddada S, Ashby J, Jacob E, Owens W. 2003. The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. Environ Health Perspect 111(12):1550-1558.
35. Khurana S, Piche M, Hollingsworth A, Venkataraman K, Tai TC. 2013. Oxidative stress and cardiovascular health: therapeutic potential of polyphenols. Can J Physiol Pharmacol 91(3):198-212.
36. Kishimoto Y, Tani M, Kondo K. 2013. Pleiotropic preventive effects of dietary polyphenols in cardiovascular diseases. Eur J Clin Nutr 67(5):532-535.
37. Krishnan K, Gagne M, Nong A, Aylward LL, Hays SM. 2010. Biomonitoring equivalents for bisphenol A (BPA). Regul Toxicol Pharmacol 58(1):18-24.
38. Krul C, Humblot C, Philippe C, Vermeulen M, van Nuenen M, Havenaar R, Rabot S. 2002. Metabolism of sinigrin (2-propenyl glucosinolate) by the human colonic microflora in a dynamic in vitro large-intestinal model. Carcinogenesis 23:1009-1016.
39. Le H, Schaldach CM, Firestone GL, Bjeldanes LF. (2003). Plant-derived 3, 3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2278:21136-21145
40. Lewerenz H-J, Bleyl DWR, Schnaak W. 1992. Effects of 5-vinyloxazolidine-2-thione on lactating rats and their sucklings. Nahrung 36:388-393.
41. OECD. 2007. OECD Guideline for the Testing of Chemicals. Uterotrophic bioassay in rodents: a short-term screening test for oestrogenic properties. Available at: http://www.epa.gov/endo/pubs/uterotrophic_OECD_guideline.pdf. Accessed Nov. 25, 2013.
42. OECD. 2013a. Series on testing and assessment: testing for endocrine disrupters. Available at: http://www.oecd.org/chemicalsafety/testing/seriesontestingandassessmenttestingforendocrinedisrupters.htm. Accessed Nov. 25, 2013.
43. OECD. 2013b. OECD guidelines for the testing of chemicals; Section 4, health effects and Section 2, effects on biotic systems. Available at: http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicals.htm. Accessed Nov. 25, 2013.
44. Patlewicz G, Simon T, Goyak K, Phillips RD, Rowlands JC, Seidel SD, Becker RA. 2013. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul Toxicol Pharmacol. 65(2):259-68.
45. Pérez-Jiménez J, Hubert J, Hooper L, Cassidy A, Manach C, Williamson G, Scalbert A. 2010. Urinary metabolites as biomarkers of polyphenol intake in humans: a systematic review. Am J Clin Nutr 92(4):801-809.
46. Price PS, Han X. 2011. Maximum cumulative ratio (MCR) as a tool for assessing the value of performing a cumulative risk assessment. Int J Environ Res Public Health 8(6):2212-2225.
47. Rachon D, Vortherms T, Seidlova-Wuttke D, Wuttke W. 2007. Dietary daidzein and puerarin do not affect pituitary LH expression but exert uterotropic effects in ovariectomized rats. Maturitas 57(2):161-170.
48. Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, Knudsen TB, Dix DJ, Kavlock RJ. 2010. Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ Health Perspect 118(12):1714-20
49. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson RS, Smith CM, Sochaski MA, Kavlock RJ, Boellmann F, Martin MT, Reif DM, Wambaugh JF, Thomas RS. 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 117:348-358.
50. Schwen RJ, Nguyen L, Plomley JB, Jackson RL. 2012. Toxicokinetics and lack of uterotropic effect of orally administered S-equol. Food Chem Toxicol 50(5):1741-1748.
51. Teeguarden JG, Calafat AM, Ye X, Doerge DR, Churchwell MI, Gunawan R, et al. 2011. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol Sci 123(1):48-57.
52. Tham DM, Gardner CD, Haskell WL. 1998. Clinical Review 97. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83(7):2223-35. Available at: http://jcem.endojournals.org/content/83/7/2223.long. Accessed Nov. 25, 2013.
53. Tham DM, Gardner CD, Haskell WL, Volkel W, Bittner N, Dekant W. 2005. Quantitation of bisphenol A and bisphenol A glucuronide in biological samples by high performance liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 33(11):1748-1757.
54. Tinwell H, Colombel S, Blanck O, Bars R, Volkel W, Kiranoglu M, Fromme H. 2008. Determination of free and total bisphenol A in human urine to assess daily uptake as a basis for a valid risk assessment. Toxicol Lett 179(3):155-162.
55. Tinwell H, Colombel S, Blanck O, Bars R. 2013. The screening of everyday life chemicals in validated assays targeting the pituitary-gonadal axis. Regul Toxicol Pharmacol. 66:184-196.
56. Wambaugh JF, Setzer RW, Reif DM, Gangwal S, Mitchell-Blackwood J, Arnot JA, Joliet O, Frame A, Rabinowitz J, Knudsen TB, Judson RS, Egeghy P, Vallero D, Cohen Hubal EA. 2013. High-throughput models for exposure-based chemical prioritization in the ExpoCast project. Environ Sci Technol. 47(15):8479-8488.
57. Wetmore BA, Wambaugh JF, Ferguson SS, Sochaski MA, Rotroff DM, Freeman K, Clewell HJ 3rd, Dix DJ, Andersen ME, Houck KA, Allen B, Judson RS, Singh R, Kavlock RJ, Richard AM, Thomas RS. 2012. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 125(1):157-174.